SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
LONG-ACTING THERAPY: THE TIME HAS COME
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
4 of
4
|
WEEK 96 EFFICACY AND SAFETY OF CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M (ABSTRACT
401)
Hans Jaeger
MVZ München am Goetheplatz, Munich, Germany
LONG-ACTING CABOTEGRAVIR+RILPIVIRINE IN OLDER ADULTS: POOLED PHASE 3 WEEK-48 RESULTS (ABSTRACT
402)
Paul Benn
ViiV Healthcare, Brentford, United Kingdom
POPPK MODELING OF Q2M IM RPV LA FOR MANAGING DOSING INTERRUPTIONS IN HIV-1 PATIENTS (ABSTRACT
403)
Herta Crauwels
Janssen Pharmaceutica, Beerse, Belgium
BICTEGRAVIR AND CABOTEGRAVIR: IN VITRO PHENOTYPIC SUSCEPTIBILITY OF HIV-1 NONGROUP M (ABSTRACT
404)
Charlène Martin
Normandie University, Rouen Cedex, France
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
4 of
4
|
